NCT06653842

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Palvella Therapeutics, Inc. · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

Conditions

• Cutaneous Venous Malformations

Interventions

Type	Name	Description
DRUG	QTORIN 3.9% rapamycin anhydrous gel	QTORIN 3.9% Rapamycin Anhydrous Gel

Timeline

• Start date: 2024-12-20
• Primary completion: 2025-11-21
• Completion: 2026-03-01
• First posted: 2024-10-22
• Last updated: 2026-03-27

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study